Clinical Trial

Glofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Study acronym: Glofit-Sel
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Assess the efficacy and safety of glofitamab in combination with selinexor for the treatment of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) in patients who have received at least two prior lines of systemic therapy.
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT07669194
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators: Zhejiang Provincial People's Hospital, The First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Tongde Hospital, Affiliated Hospital of Jiaxing University, Shaoxing People's Hospital, Shaoxing Central Hospital, Zhuji People's Hospital of Zhejiang Province
Conditions Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment 30 participants
Start Date 2026-06-10
Primary Completion 2029-04-30 (estimated)
Study Completion 2029-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-25